Natasha Martin

Title(s)Professor, Medicine
SchoolVc-health Sciences-schools
Address9500 Gilman Drive #
La Jolla CA 92093
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Oxford University, Oxford, UKDPhil/PhD2009Mathematical biology
    Stanford University, Palo Alto, CABS2003Mathematics, biology

    Collapse Overview 
    Collapse Overview
    Dr. Natasha Martin is an infectious disease economic modeler who develops dynamic transmission models to evaluate the impact and cost-effectiveness of public health interventions. She is currently a Professor in the Division of Infectious Diseases and Global Public Health at the University of California San Diego and holds an honorary senior lecturer position at the University of Bristol. She directs the NIDA-funded T32 program in Substance Use, HIV, and related syndemics along with MPI Steffanie Strathdee, which trains pre and postdoctoral fellows. She is the MPI on the UC GloCal Health Fellowship, which provides one year of funding to conduct global health research abroad (https://ucghi.universityofcalifornia.edu/fellowships/glocal-health-fellowship). Finally, she is co-director of the Biostatistics and Modeling Core of the University of California San Diego Center for AIDS Research (UCSD CFAR). Her primary research has focused on modeling the impact and cost-effectiveness of interventions to prevent HIV, hepatitis C virus, and overdose among people who use drugs. She is the principal investigator (PI) of a NIAID/NIDA-funded R01 optimizing HIV and HCV prevention portfolios among people who inject drugs in 108 countries, MPI on a NIMH funded R01 on using molecular epidemiology and modeling to optimize HIV resource allocation in Miami-Dade county, and MPI a CDC-funded outbreak analytics and modeling center. Her modeling work informed the WHO guidelines “When to start ART in people living with HIV (2013)”, “Hepatitis C testing, care, and treatment (2013)” and the WHO “Global Health Sector Strategy on Viral Hepatitis 2016-2021”. She is the Vice President of the International Network on Health and Hepatitis in Substance Users (INHSU) and an associate editor of the journal Addiction.

    Collapse Research 
    Collapse Research Activities and Funding
    Miami Dade County ASsessment of Phylogenetics to Improve Resource Equity: MD ASPIRE
    NIMH R01MH132151Jul 1, 2022 - Jun 30, 2027
    Role: MPI
    Description: To date, the use of HIV molecular surveillance has not been linked to a reduction in HIV incidence. The proposed project will perform secondary analyses of coded and de-identified public health HIV surveillance data from the Los Angeles County (LAC) Health Department. The study team will engage key stakeholder populations and use regional estimates of HIV transmission and HIV program data to project the impact of alternative strategies for the optimal allocation of resources to LAC HIV prevention programs relevant to EHE targets.
    Simulation Modeling to Support the Public Health Response to the Opioid Crisis in North America
    NIH R13DA052198Jun 1, 2021 - May 31, 2024
    Role: Co-Principal Investigator
    Ethno-epidemiology of HCV, HIV and Overdose associated with Drug Markets and Drug Tourism
    NIH/NIDA R01DA049644Apr 1, 2020 - Jan 31, 2025
    Role: Co-Investigator
    Optimizing HIV prevention portfolios targeting people who inject drugs using dynamic economic modeling
    NIH R01AI147490Aug 7, 2019 - Jul 31, 2023
    Role: Principal Investigator
    Integrating HCV services into HIV programs for PWID in India
    NIH R01AI145555Jul 8, 2019 - Jun 30, 2024
    Role: Co-Investigator
    University of California, San Diego, Center for AIDS Research
    NIH 5 P30 AI036214Apr 1, 2018 - Mar 31, 2023
    Role: Co-Director, Biostatistics and Modeling Core
    Modeling Structural HIV Determinants in Substance Users and related populations
    NIH R01DA037773Apr 1, 2015 - Dec 31, 2018
    Role: Principal Investigator
    The Impact of HCV Treatment in HIV/HCV coinfected and HCV monoinfected Incarcerated Persons on HCV Elimination
    NIH R01DA013806Sep 20, 2000 - Aug 31, 2025
    Role: Co-Investigator
    Modeling opioid overdose and prevention in Australia
    Australian NHMRC Dec 31, 2023
    Role: Co-I
    Evaluating the Population Impact of Hepatitis C Direct Acting Antiviral Treatment as Prevention for People Who Inject Drugs (EPIToPe).
    UK National Institute for Health Research Feb 1, 2023
    Role: Co-investigator
    HCV elimination among men who have sex with men in Germany
    Gilead Jun 1, 2022
    Role: Co-investigator
    Impact of direct acting antivirals uptake in controlling hepatitis C epidemic and modeling interventions for hepatitis C elimination among HIV-infected persons in San Diego
    Gilead Jan 1, 2021
    Role: Co-PI
    Modeling HCV elimination among HIV-infected men who have sex with men and people who inject drugs
    Gilead Dec 31, 2020
    Role: Principal Investigator
    Testing and comparing study designs for evaluating HCV treatment as prevention (TasP) impact in a real world setting
    Merck Dec 1, 2020
    Role: Principal Investigator
    Cost-effectiveness of HCV testing and treatment in pregnant women
    Gilead Apr 30, 2020
    Role: Principal Investigator
    Surveillance and Treatment of Prisoners with hepatitis C (STOP-C)
    Australian NHMRC Dec 31, 2019
    Role: Co-Investigator
    Description: To test HCV treatment as prevention among prisoners in New South Wales, Australia. Overseeing modeling to inform trial design, implementation and evaluation.

    Collapse ORNG Applications 
    Collapse Featured Publications

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Modeling as Visioning: Exploring the Impact of Criminal Justice Reform on Health of Populations with Substance Use Disorders. MDM Policy Pract. 2023 Jul-Dec; 8(2):23814683231202984. Martin NK, Beletsky L, Linas BP, Bayoumi A, Pollack H, Larney S. PMID: 37841498; PMCID: PMC10568988.
      View in: PubMed   Mentions:
    2. Unit costs of needle and syringe program provision: a global systematic review and cost extrapolation. AIDS. 2023 12 01; 37(15):2389-2397. Killion JA, Magana C, Cepeda JA, Vo A, Hernandez M, Cyr CL, Heskett KM, Wilson DP, Graff Zivin J, Zúñiga ML, Pines HA, Garfein RS, Vickerman P, Terris-Prestholt F, Wynn A, Martin NK. PMID: 37773035; PMCID: PMC10653296.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    3. Determining herd immunity thresholds for hepatitis A virus transmission to inform vaccination strategies among people who inject drugs in 16 U.S. States. Clin Infect Dis. 2023 Sep 21. Yang J, Lo NC, Dankwa EA, Donnelly CA, Gupta R, Montgomery MP, Weng MK, Martin NK. PMID: 37738564.
      View in: PubMed   Mentions:    Fields:    
    4. Annual N95 respirator fit-testing: an unnecessary burden on healthcare. Infect Control Hosp Epidemiol. 2024 Feb; 45(2):250-252. Martin TCS, Curtin G, Martin NK, Torriani FJ. PMID: 37646178; PMCID: PMC10877532.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    5. Health-related quality of life among people who inject drugs in Australia. Qual Life Res. 2023 Nov; 32(11):3195-3207. Cheng Q, Bajis S, Cunningham E, Shih STF, Schulz M, Marshall AD, Martin NK, Miners A, Hajarizadeh B, Wiseman V, Dore GJ, Grebely J. PMID: 37351701; PMCID: PMC10522523.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    6. Estimating the impact of a police education program on hepatitis C virus transmission and disease burden among people who inject drugs in Tijuana, Mexico: A dynamic modeling analysis. Addiction. 2023 09; 118(9):1763-1774. Rivera Saldana CD, Abramovitz D, Beletsky L, Borquez A, Kiene S, Marquez LK, Patton T, Strathdee S, Zúñiga ML, Martin NK, Cepeda J. PMID: 37039246; PMCID: PMC10524658.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    7. Hepatitis C Virus Micro-elimination Among People With HIV in San Diego: Are We on Track? Open Forum Infect Dis. 2023 Apr; 10(4):ofad153. Cheema JS, Mathews WC, Wynn A, Bamford LB, Torriani FJ, Hill LA, Rajagopal AV, Yin J, Jain S, Garfein RS, Cachay ER, Martin NK. PMID: 37065984; PMCID: PMC10099471.
      View in: PubMed   Mentions:
    8. Safer at school early alert: an observational study of wastewater and surface monitoring to detect COVID-19 in elementary schools. Lancet Reg Health Am. 2023 Mar; 19:100449. Fielding-Miller R, Karthikeyan S, Gaines T, Garfein RS, Salido RA, Cantu VJ, Kohn L, Martin NK, Wynn A, Wijaya C, Flores M, Omaleki V, Majnoonian A, Gonzalez-Zuniga P, Nguyen M, Vo AV, Le T, Duong D, Hassani A, Tweeten S, Jepsen K, Henson B, Hakim A, Birmingham A, De Hoff P, Mark AM, Nasamran CA, Rosenthal SB, Moshiri N, Fisch KM, Humphrey G, Farmer S, Tubb HM, Valles T, Morris J, Kang J, Khaleghi B, Young C, Akel AD, Eilert S, Eno J, Curewitz K, Laurent LC, Rosing T, Knight R, SEARCH. PMID: 36844610; PMCID: PMC9939935.
      View in: PubMed   Mentions: 14  
    9. Wastewater and surface monitoring to detect COVID-19 in elementary school settings: The Safer at School Early Alert project. medRxiv. 2023 Jan 25. Fielding-Miller R, Karthikeyan S, Gaines T, Garfein RS, Salido RA, Cantu VJ, Kohn L, Martin NK, Wynn A, Wijaya C, Flores M, Omaleki V, Majnoonian A, Gonzalez-Zuniga P, Nguyen M, Vo AV, Le T, Duong D, Hassani A, Tweeten S, Jepsen K, Henson B, Hakim A, Birmingham A, De Hoff P, Mark AM, Nasamran CA, Rosenthal SB, Moshiri N, Fisch KM, Humphrey G, Farmer S, Tubb HM, Valles T, Morris J, Kang J, Khaleghi B, Young C, Akel AD, Eilert S, Eno J, Curewitz K, Laurent LC, Rosing T, Knight R. PMID: 34704096; PMCID: PMC8547528.
      View in: PubMed   Mentions: 1  
    10. Hepatitis C Virus Reinfection Following Direct-Acting Antiviral Treatment in the Prison Setting: The SToP-C Study. Clin Infect Dis. 2022 Nov 14; 75(10):1809-1819. Carson JM, Dore GJ, Lloyd AR, Grebely J, Byrne M, Cunningham E, Amin J, Vickerman P, Martin NK, Treloar C, Martinello M, Matthews GV, Hajarizadeh B, Surveillance and Treatment of Prisoners With Hepatitis C (SToP-C) Study Group . PMID: 35362522.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    11. Prison-based interventions are key to achieving HCV elimination among people who inject drugs in New South Wales, Australia: A modelling study. Liver Int. 2023 03; 43(3):569-579. Stone J, Lim AG, Dore GJ, Borquez A, Geddes L, Gray R, Grebely J, Hajarizadeh B, Iversen J, Maher L, Valerio H, Martin NK, Hickman M, Lloyd AR, Vickerman P. PMID: 36305315; PMCID: PMC10308445.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    12. A stakeholder-driven framework for measuring potential change in the health risks of people who inject drugs (PWID) during the COVID-19 pandemic. Int J Drug Policy. 2022 Oct 17; 110:103889. Bradley H, Austin C, Allen ST, Asher A, Bartholomew TS, Board A, Borquez A, Buchacz K, Carter A, Cooper HLF, Feinberg J, Furukawa N, Genberg B, Gorbach PM, Hagan H, Huriaux E, Hurley H, Luisi N, Martin NK, Rosenberg ES, Strathdee SA, Jarlais DCD. PMID: 36343431; PMCID: PMC9574463.
      View in: PubMed   Mentions: 1     Fields:    
    13. Changes in supervised consumption site use and emergency interventions in Montréal, Canada in the first twelve months of the COVID-19 pandemic: An interrupted time series study. Int J Drug Policy. 2022 12; 110:103894. Zolopa C, Brothers TD, Leclerc P, Mary JF, Morissette C, Bruneau J, Hyshka E, Martin NK, Larney S. PMID: 36308892; PMCID: PMC9574459.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    14. Modelling the contribution of incarceration and public health oriented drug law reform to HCV transmission and elimination among PWID in Tijuana, Mexico. Int J Drug Policy. 2022 Dec; 110:103878. Saldana CDR, Beletsky L, Borquez A, Kiene SM, Marquez LK, Strathdee SA, Zúñiga ML, Cepeda J, Martin NK. PMID: 36242829; PMCID: PMC9841890.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCellsPHPublic Health
    15. Sustained Impact of the Coronavirus Disease 2019 Pandemic on Hepatitis C Virus Treatment Initiations in the United States. Clin Infect Dis. 2022 08 24; 75(1):e955-e961. Hoenigl M, Abramovitz D, Flores Ortega RE, Martin NK, Reau N. PMID: 35234860; PMCID: PMC9129135.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCellsPHPublic Health
    16. Network methods and design of randomized trials: Application to investigation of COVID-19 vaccination boosters. Clin Trials. 2022 08; 19(4):363-374. DeGruttola V, Goyal R, Martin NK, Wang R. PMID: 35894099; PMCID: PMC9378506.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCellsPHPublic Health
    17. Wastewater sequencing reveals early cryptic SARS-CoV-2 variant transmission. Nature. 2022 09; 609(7925):101-108. Karthikeyan S, Levy JI, De Hoff P, Humphrey G, Birmingham A, Jepsen K, Farmer S, Tubb HM, Valles T, Tribelhorn CE, Tsai R, Aigner S, Sathe S, Moshiri N, Henson B, Mark AM, Hakim A, Baer NA, Barber T, Belda-Ferre P, Chacón M, Cheung W, Cresini ES, Eisner ER, Lastrella AL, Lawrence ES, Marotz CA, Ngo TT, Ostrander T, Plascencia A, Salido RA, Seaver P, Smoot EW, McDonald D, Neuhard RM, Scioscia AL, Satterlund AM, Simmons EH, Abelman DB, Brenner D, Bruner JC, Buckley A, Ellison M, Gattas J, Gonias SL, Hale M, Hawkins F, Ikeda L, Jhaveri H, Johnson T, Kellen V, Kremer B, Matthews G, McLawhon RW, Ouillet P, Park D, Pradenas A, Reed S, Riggs L, Sanders A, Sollenberger B, Song A, White B, Winbush T, Aceves CM, Anderson C, Gangavarapu K, Hufbauer E, Kurzban E, Lee J, Matteson NL, Parker E, Perkins SA, Ramesh KS, Robles-Sikisaka R, Schwab MA, Spencer E, Wohl S, Nicholson L, McHardy IH, Dimmock DP, Hobbs CA, Bakhtar O, Harding A, Mendoza A, Bolze A, Becker D, Cirulli ET, Isaksson M, Schiabor Barrett KM, Washington NL, Malone JD, Schafer AM, Gurfield N, Stous S, Fielding-Miller R, Garfein RS, Gaines T, Anderson C, Martin NK, Schooley R, Austin B, MacCannell DR, Kingsmore SF, Lee W, Shah S, McDonald E, Yu AT, Zeller M, Fisch KM, Longhurst C, Maysent P, Pride D, Khosla PK, Laurent LC, Yeo GW, Andersen KG, Knight R. PMID: 35798029; PMCID: PMC9433318.
      View in: PubMed   Mentions: 105     Fields:    Translation:HumansCellsPHPublic Health
    18. Establishing a framework towards monitoring HCV microelimination among men who have sex with men living with HIV in Germany: A modeling analysis. PLoS One. 2022; 17(5):e0267853. Marquez LK, Ingiliz P, Boesecke C, Krznaric I, Schewe K, Lutz T, Mauss S, Christensen S, Rockstroh JK, Jain S, He F, Wertheim JO, Martin NK. PMID: 35551326; PMCID: PMC9098082.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCellsPHPublic Health
    19. Fatal overdose: Predicting to prevent. Int J Drug Policy. 2022 06; 104:103677. Borquez A, Martin NK. PMID: 35550852; PMCID: PMC9347029.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    20. Wastewater sequencing uncovers early, cryptic SARS-CoV-2 variant transmission. medRxiv. 2022 Apr 04. Karthikeyan S, Levy JI, De Hoff P, Humphrey G, Birmingham A, Jepsen K, Farmer S, Tubb HM, Valles T, Tribelhorn CE, Tsai R, Aigner S, Sathe S, Moshiri N, Henson B, Mark AM, Hakim A, Baer NA, Barber T, Belda-Ferre P, Chacón M, Cheung W, Cresini ES, Eisner ER, Lastrella AL, Lawrence ES, Marotz CA, Ngo TT, Ostrander T, Plascencia A, Salido RA, Seaver P, Smoot EW, McDonald D, Neuhard RM, Scioscia AL, Satterlund AM, Simmons EH, Abelman DB, Brenner D, Bruner JC, Buckley A, Ellison M, Gattas J, Gonias SL, Hale M, Hawkins F, Ikeda L, Jhaveri H, Johnson T, Kellen V, Kremer B, Matthews G, McLawhon RW, Ouillet P, Park D, Pradenas A, Reed S, Riggs L, Sanders A, Sollenberger B, Song A, White B, Winbush T, Aceves CM, Anderson C, Gangavarapu K, Hufbauer E, Kurzban E, Lee J, Matteson NL, Parker E, Perkins SA, Ramesh KS, Robles-Sikisaka R, Schwab MA, Spencer E, Wohl S, Nicholson L, Mchardy IH, Dimmock DP, Hobbs CA, Bakhtar O, Harding A, Mendoza A, Bolze A, Becker D, Cirulli ET, Isaksson M, Barrett KMS, Washington NL, Malone JD, Schafer AM, Gurfield N, Stous S, Fielding-Miller R, Garfein RS, Gaines T, Anderson C, Martin NK, Schooley R, Austin B, MacCannell DR, Kingsmore SF, Lee W, Shah S, McDonald E, Yu AT, Zeller M, Fisch KM, Longhurst C, Maysent P, Pride D, Khosla PK, Laurent LC, Yeo GW, Andersen KG, Knight R. PMID: 35411350; PMCID: PMC8996633.
      View in: PubMed   Mentions:
    21. A gender lens is needed in hepatitis C elimination research. Int J Drug Policy. 2022 05; 103:103654. Larney S, Madden A, Marshall AD, Martin NK, Treloar C. PMID: 35306279.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCellsPHPublic Health
    22. Methods and indicators to validate country reductions in incidence of hepatitis C virus infection to elimination levels set by WHO. Lancet Gastroenterol Hepatol. 2022 04; 7(4):353-366. Artenie A, Luhmann N, Lim AG, Fraser H, Ward Z, Stone J, MacGregor L, Walker JG, Trickey A, Marquez LK, Abu-Raddad LJ, Ayoub HH, Walsh N, Hickman M, Martin NK, Easterbrook P, Vickerman P. PMID: 35122713; PMCID: PMC10644895.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    23. The contribution of unstable housing to HIV and hepatitis C virus transmission among people who inject drugs globally, regionally, and at country level: a modelling study. Lancet Public Health. 2022 02; 7(2):e136-e145. Stone J, Artenie A, Hickman M, Martin NK, Degenhardt L, Fraser H, Vickerman P. PMID: 35012711; PMCID: PMC8848679.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    24. Hepatitis C elimination among people who inject drugs in Mexico during the COVID-19 pandemic. Gac Med Mex. 2022; 158(2):110-113. Márquez LK, Borquez A, Fleiz C, Magis-Rodríguez C, Rangel G, Strathdee SA, Martin NK. PMID: 35763823; PMCID: PMC10589063.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCellsPHPublic Health
    25. Bridging the Gap Between Pilot and Scale-Up: A Model of Antenatal Testing for Curable Sexually Transmitted Infections From Botswana. Sex Transm Dis. 2022 01 01; 49(1):59-66. Wynn A, Moucheraud C, Martin NK, Morroni C, Ramogola-Masire D, Klausner JD, Leibowitz A. PMID: 34310524; PMCID: PMC8663512.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    26. Modeling the population-level impact of opioid agonist treatment on mortality among people accessing treatment between 2001 and 2020 in New South Wales, Australia. Addiction. 2022 05; 117(5):1338-1352. Chaillon A, Bharat C, Stone J, Jones N, Degenhardt L, Larney S, Farrell M, Vickerman P, Hickman M, Martin NK, Bórquez A. PMID: 34729841; PMCID: PMC9299987.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    27. The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet. 2022 01 01; 399(10319):61-116. Karlsen TH, Sheron N, Zelber-Sagi S, Carrieri P, Dusheiko G, Bugianesi E, Pryke R, Hutchinson SJ, Sangro B, Martin NK, Cecchini M, Dirac MA, Belloni A, Serra-Burriel M, Ponsioen CY, Sheena B, Lerouge A, Devaux M, Scott N, Hellard M, Verkade HJ, Sturm E, Marchesini G, Yki-Järvinen H, Byrne CD, Targher G, Tur-Sinai A, Barrett D, Ninburg M, Reic T, Taylor A, Rhodes T, Treloar C, Petersen C, Schramm C, Flisiak R, Simonova MY, Pares A, Johnson P, Cucchetti A, Graupera I, Lionis C, Pose E, Fabrellas N, Ma AT, Mendive JM, Mazzaferro V, Rutter H, Cortez-Pinto H, Kelly D, Burton R, Lazarus JV, Ginès P, Buti M, Newsome PN, Burra P, Manns MP. PMID: 34863359.
      View in: PubMed   Mentions: 94     Fields:    Translation:Humans
    28. Prevalence and correlates of SARS-CoV-2 seropositivity among people who inject drugs in the San Diego-Tijuana border region. PLoS One. 2021; 16(11):e0260286. Strathdee SA, Abramovitz D, Harvey-Vera A, Vera CF, Rangel G, Artamonova I, Chaillon A, Ignacio C, Calderon A, Martin NK, Patterson TL. PMID: 34807963; PMCID: PMC8608290.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    29. Safe reopening of college campuses during COVID-19: The University of California experience in Fall 2020. PLoS One. 2021; 16(11):e0258738. Pollock BH, Kilpatrick AM, Eisenman DP, Elton KL, Rutherford GW, Boden-Albala BM, Souleles DM, Polito LE, Martin NK, Byington CL. PMID: 34735480; PMCID: PMC8568179.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCellsPHPublic Health
    30. Cost-effectiveness of Antenatal Rescreening Among Pregnant Women for Hepatitis C in the United States. Clin Infect Dis. 2021 11 02; 73(9):e3355-e3357. Chaillon A, Wynn A, Kushner T, Reau N, Martin NK. PMID: 32282879; PMCID: PMC8563211.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCellsPHPublic Health
    31. Evaluation of Severe Acute Respiratory Syndrome Coronavirus 2 Transmission Mitigation Strategies on a University Campus Using an Agent-Based Network Model. Clin Infect Dis. 2021 11 02; 73(9):1735-1741. Goyal R, Hotchkiss J, Schooley RT, De Gruttola V, Martin NK. PMID: 33462589; PMCID: PMC7929036.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCellsPHPublic Health
    32. Estimating vaccination threshold and impact in the 2017-2019 hepatitis A virus outbreak among persons experiencing homelessness or who use drugs in Louisville, Kentucky, United States. Vaccine. 2021 12 03; 39(49):7182-7190. Dankwa EA, Donnelly CA, Brouwer AF, Zhao R, Montgomery MP, Weng MK, Martin NK. PMID: 34686394; PMCID: PMC9128446.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCellsPHPublic Health
    33. Evaluating the Prevention Benefit of HCV Treatment: Modeling the SToP-C Treatment as Prevention Study in Prisons. Hepatology. 2021 11; 74(5):2366-2379. Lim AG, Stone J, Hajarizadeh B, Byrne M, Chambers GM, Martin NK, Grebely J, Dore GJ, Lloyd AR, Vickerman P. PMID: 34105797.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    34. Assessing HIV and overdose risks for people who use drugs exposed to compulsory drug abstinence programs (CDAP): A systematic review and meta-analysis. Int J Drug Policy. 2021 10; 96:103401. Vo AT, Magana C, Hickman M, Borquez A, Beletsky L, Martin NK, Cepeda JA. PMID: 34389218; PMCID: PMC9027650.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    35. Rapid, Large-Scale Wastewater Surveillance and Automated Reporting System Enable Early Detection of Nearly 85% of COVID-19 Cases on a University Campus. mSystems. 2021 Aug 31; 6(4):e0079321. Karthikeyan S, Nguyen A, McDonald D, Zong Y, Ronquillo N, Ren J, Zou J, Farmer S, Humphrey G, Henderson D, Javidi T, Messer K, Anderson C, Schooley R, Martin NK, Knight R. PMID: 34374562; PMCID: PMC8409724.
      View in: PubMed   Mentions: 56     Fields:    
    36. Overlapping Key Populations and HIV Transmission in Tijuana, Mexico: A Modelling Analysis of Epidemic Drivers. AIDS Behav. 2021 Nov; 25(11):3814-3827. Fraser H, Borquez A, Stone J, Abramovitz D, Brouwer KC, Goodman-Meza D, Hickman M, Patterson TL, Silverman J, Smith L, Strathdee SA, Martin NK, Vickerman P. PMID: 34216285; PMCID: PMC8560668.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansPHPublic Health
    37. Identifying counties at risk of high overdose mortality burden during the emerging fentanyl epidemic in the USA: a predictive statistical modelling study. Lancet Public Health. 2021 10; 6(10):e720-e728. Marks C, Abramovitz D, Donnelly CA, Carrasco-Escobar G, Carrasco-Hernández R, Ciccarone D, González-Izquierdo A, Martin NK, Strathdee SA, Smith DM, Bórquez A. PMID: 34118194; PMCID: PMC8565591.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansPHPublic Health
    38. The estimated hepatitis C seroprevalence and key population sizes in San Diego in 2018. PLoS One. 2021; 16(6):e0251635. Wynn A, Tweeten S, McDonald E, Wooten W, Lucas K, Cyr CL, Hernandez M, Ramirez F, VanWormer C, Suckow S, Ramers CB, Martin NK. PMID: 34106932; PMCID: PMC8189442.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    39. Articulating the Trauma-Informed Theory of Individual Health Behavior. Stress Health. 2022 Feb; 38(1):154-162. Marks C, Pearson JL, Zúñiga ML, Martin N, Werb D, Smith LR. PMID: 34009751; PMCID: PMC9035290.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    40. Discussion of article by Ellenberg and Morris. Stat Med. 2021 05 20; 40(11):2511-2512. De Gruttola V, Goyal R, Martin NK. PMID: 33963584.
      View in: PubMed   Mentions:    Fields:    
    41. Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study. Lancet Gastroenterol Hepatol. 2021 07; 6(7):533-546. Hajarizadeh B, Grebely J, Byrne M, Marks P, Amin J, McManus H, Butler T, Cunningham EB, Vickerman P, Martin NK, McHutchison JG, Brainard DM, Treloar C, Chambers GM, Grant L, Mcgrath C, Lloyd AR, Dore GJ, SToP-C study group. PMID: 33965006.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    42. The cost-effectiveness of case-finding strategies for achieving hepatitis C elimination among men who have sex with men in the UK. J Viral Hepat. 2021 06; 28(6):897-908. Macgregor L, Ward Z, Martin NK, Nicholls J, Desai M, Hickson F, Weatherburn P, Hickman M, Vickerman P. PMID: 33759257; PMCID: PMC9132016.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    43. Cost-effectiveness of hepatitis C virus (HCV) elimination strategies among people who inject drugs (PWID) in Tijuana, Mexico. Addiction. 2021 10; 116(10):2734-2745. Marquez LK, Fleiz C, Burgos JL, Cepeda JA, McIntosh C, Garfein RS, Kiene SM, Brodine S, Strathdee SA, Martin NK. PMID: 33620750; PMCID: PMC8380744.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    44. Impact of cumulative incarceration and the post-release period on syringe-sharing among people who inject drugs in Tijuana, Mexico: a longitudinal analysis. Addiction. 2021 10; 116(10):2724-2733. Rivera Saldana CD, Beletsky L, Borquez A, Kiene SM, Strathdee SA, Zúñiga ML, Martin NK, Cepeda J. PMID: 33620749; PMCID: PMC8380753.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    45. Cost and cost-effectiveness of a real-world HCV treatment program among HIV-infected individuals in Myanmar. BMJ Glob Health. 2021 02; 6(2). Marquez LK, Chaillon A, Soe KP, Johnson DC, Zosso JM, Incerti A, Loarec A, Nguyen A, Walker JG, Mafirakureva N, Lo Re Iii V, Wynn A, McIntosh C, Kiene SM, Brodine S, Garfein RS, Vickerman P, Martin NK. PMID: 33627360; PMCID: PMC7908309.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    46. Evaluating the power of the causal impact method in observational studies of HCV treatment as prevention. Stat Commun Infect Dis. 2021 Jan 01; 13(1):20200005. Samartsidis P, Martin NN, De Gruttola V, De Vocht F, Hutchinson S, Lok JJ, Puenpatom A, Wang R, Hickman M, De Angelis D. PMID: 35880998; PMCID: PMC9204771.
      View in: PubMed   Mentions: 1  
    47. What the HIV Pandemic Experience Can Teach the United States About the COVID-19 Response. J Acquir Immune Defic Syndr. 2021 01 01; 86(1):1-10. Strathdee SA, Martin NK, Pitpitan EV, Stockman JK, Smith DM. PMID: 33027152; PMCID: PMC7727321.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansPHPublic Health
    48. Screening for Sexually Transmitted Infections During Hepatitis C Treatment to Predict Reinfection Among People With HIV. Open Forum Infect Dis. 2021 Feb; 8(2):ofaa643. Hill LA, Martin NK, Torriani FJ, Jain S, Qin H, Mathews WC, Cachay ER. PMID: 33553480; PMCID: PMC7850126.
      View in: PubMed   Mentions: 3  
    49. Cost-effectiveness of using hepatitis C viremic hearts for transplantation into HCV-negative recipients. Am J Transplant. 2021 02; 21(2):657-668. Logan C, Yumul I, Cepeda J, Pretorius V, Adler E, Aslam S, Martin NK. PMID: 32777173; PMCID: PMC8216294.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    50. What is required for achieving hepatitis C virus elimination in Singapore? A modeling study. J Gastroenterol Hepatol. 2021 Apr; 36(4):1110-1117. Chaillon A, Thurairajah PH, Hsiang JC, Martin NK. PMID: 32777859; PMCID: PMC8174139.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansPHPublic Health
    51. The role of barriers to care on the propensity for hepatitis C virus nonreferral among people living with HIV. AIDS. 2020 09 01; 34(11):1681-1683. Cachay ER, Torriani FJ, Hill L, Jain S, Del Real A, Qin H, Martin N, Mathews WC. PMID: 32769765; PMCID: PMC8189281.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    52. What is needed to achieve HCV microelimination among HIV-infected populations in Andalusia, Spain: a modeling analysis. BMC Infect Dis. 2020 Aug 08; 20(1):588. Skaathun B, Borquez A, Rivero-Juarez A, Mehta SR, Tellez F, Castaño-Carracedo M, Merino D, Palacios R, Macías J, Rivero A, Martin NK. PMID: 32770955; PMCID: PMC7414743.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    53. Estimating the contribution of stimulant injection to HIV and HCV epidemics among people who inject drugs and implications for harm reduction: A modeling analysis. Drug Alcohol Depend. 2020 Aug 01; 213:108135. Cepeda JA, Vickerman P, Bruneau J, Zang G, Borquez A, Farrell M, Degenhardt L, Martin NK. PMID: 32603976; PMCID: PMC7829087.
      View in: PubMed   Mentions: 8     Fields:    
    54. Modelling testing frequencies required for early detection of a SARS-CoV-2 outbreak on a university campus. medRxiv. 2020 Jun 01. Martin N, Schooley RT, De Gruttola V. PMID: 32577676; PMCID: PMC7302280.
      View in: PubMed   Mentions: 2  
    55. Integrating HIV pre-exposure prophylaxis and harm reduction among men who have sex with men and transgender women to address intersecting harms associated with stimulant use: a modelling study. J Int AIDS Soc. 2020 06; 23 Suppl 1:e25495. Bórquez A, Rich K, Farrell M, Degenhardt L, McKetin R, Tran LT, Cepeda J, Silva-Santisteban A, Konda K, Cáceres CF, Kelly S, Altice FL, Martin NK. PMID: 32562365; PMCID: PMC7305413.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansPHPublic Health
    56. Modelling integrated antiretroviral treatment and harm reduction services on HIV and overdose among people who inject drugs in Tijuana, Mexico. J Int AIDS Soc. 2020 06; 23 Suppl 1:e25493. Cepeda JA, Bórquez A, Magana C, Vo A, Rafful C, Rangel G, Medina-Mora ME, Strathdee S, Martin NK. PMID: 32562375; PMCID: PMC7305416.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansPHPublic Health
    57. The use of mathematical modeling to inform drug policy making. Int J Drug Policy. 2021 02; 88:102759. Martin NK, Vickerman P. PMID: 32312601; PMCID: PMC7164851.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    58. Is hepatitis C virus (HCV) elimination achievable among people who inject drugs in Tijuana, Mexico? A modeling analysis. Int J Drug Policy. 2021 02; 88:102710. Marquez LK, Cepeda JA, Bórquez A, Strathdee SA, Gonzalez-Zúñiga PE, Fleiz C, Rafful C, Garfein RS, Kiene SM, Brodine S, Martin NK. PMID: 32165050; PMCID: PMC8133359.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    59. Effects and cost of different strategies to eliminate hepatitis C virus transmission in Pakistan: a modelling analysis. Lancet Glob Health. 2020 03; 8(3):e440-e450. Lim AG, Walker JG, Mafirakureva N, Khalid GG, Qureshi H, Mahmood H, Trickey A, Fraser H, Aslam K, Falq G, Fortas C, Zahid H, Naveed A, Auat R, Saeed Q, Davies CF, Mukandavire C, Glass N, Maman D, Martin NK, Hickman M, May MT, Hamid S, Loarec A, Averhoff F, Vickerman P. PMID: 32087176; PMCID: PMC7295205.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansPHPublic Health
    60. Cost-effectiveness of the HepCATT intervention in specialist drug clinics to improve case-finding and engagement with HCV treatment for people who inject drugs in England. Addiction. 2020 08; 115(8):1509-1521. Ward Z, Reynolds R, Campbell L, Martin NK, Harrison G, Irving W, Hickman M, Vickerman P. PMID: 31984606; PMCID: PMC10762643.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    61. Prisons can also improve drug user health in the community. Addiction. 2020 05; 115(5):914-915. Martin NK, Hickman M, Spaulding AC, Vickerman P. PMID: 32026531.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    62. Scaling up screening and treatment for elimination of hepatitis C among men who have sex with men in the era of HIV pre-exposure prophylaxis. EClinicalMedicine. 2020 Feb; 19:100217. Macgregor L, Desai M, Martin NK, Nicholls J, Hickson F, Weatherburn P, Hickman M, Vickerman P. PMID: 32140664; PMCID: PMC7046521.
      View in: PubMed   Mentions: 10  
    63. Interim effect evaluation of the hepatitis C elimination programme in Georgia: a modelling study. Lancet Glob Health. 2020 02; 8(2):e244-e253. Walker JG, Kuchuloria T, Sergeenko D, Fraser H, Lim AG, Shadaker S, Hagan L, Gamkrelidze A, Kvaratskhelia V, Gvinjilia L, Aladashvili M, Asatiani A, Baliashvili D, Butsashvili M, Chikovani I, Khonelidze I, Kirtadze I, Kuniholm MH, Otiashvili D, Sharvadze L, Stvilia K, Tsertsvadze T, Zakalashvili M, Hickman M, Martin NK, Morgan J, Nasrullah M, Averhoff F, Vickerman P. PMID: 31864917; PMCID: PMC7025283.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansPHPublic Health
    64. Opioid agonist treatment scale-up and the initiation of injection drug use: A dynamic modeling analysis. PLoS Med. 2019 11; 16(11):e1002973. Marks C, Borquez A, Jain S, Sun X, Strathdee SA, Garfein RS, Milloy MJ, DeBeck K, Cepeda JA, Werb D, Martin NK. PMID: 31770373; PMCID: PMC6879119.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    65. Cost-effectiveness of Universal Hepatitis C Virus Screening of Pregnant Women in the United States. Clin Infect Dis. 2019 11 13; 69(11):1888-1895. Chaillon A, Rand EB, Reau N, Martin NK. PMID: 30689769; PMCID: PMC7188080.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCells
    66. Responding to global stimulant use: challenges and opportunities. Lancet. 2019 11 02; 394(10209):1652-1667. Farrell M, Martin NK, Stockings E, Bórquez A, Cepeda JA, Degenhardt L, Ali R, Tran LT, Rehm J, Torrens M, Shoptaw S, McKetin R. PMID: 31668409; PMCID: PMC6924572.
      View in: PubMed   Mentions: 69     Fields:    Translation:Humans
    67. Eliminating Hepatitis C Virus Among Human Immunodeficiency Virus-Infected Men Who Have Sex With Men in Berlin: A Modeling Analysis. J Infect Dis. 2019 10 08; 220(10):1635-1644. Martin NK, Jansen K, An der Heiden M, Boesecke C, Boyd A, Schewe K, Baumgarten A, Lutz T, Christensen S, Thielen A, Mauss S, Rockstroh JK, Skaathun B, Ingiliz P. PMID: 31301142; PMCID: PMC7360352.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansPHPublic Health
    68. Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) - a natural experiment (protocol). BMJ Open. 2019 09 24; 9(9):e029538. Hickman M, Dillon JF, Elliott L, De Angelis D, Vickerman P, Foster G, Donnan P, Eriksen A, Flowers P, Goldberg D, Hollingworth W, Ijaz S, Liddell D, Mandal S, Martin N, Beer LJZ, Drysdale K, Fraser H, Glass R, Graham L, Gunson RN, Hamilton E, Harris H, Harris M, Harris R, Heinsbroek E, Hope V, Horwood J, Inglis SK, Innes H, Lane A, Meadows J, McAuley A, Metcalfe C, Migchelsen S, Murray A, Myring G, Palmateer NE, Presanis A, Radley A, Ramsay M, Samartsidis P, Simmons R, Sinka K, Vojt G, Ward Z, Whiteley D, Yeung A, Hutchinson SJ. PMID: 31551376; PMCID: PMC6773339.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    69. Modelling the potential prevention benefits of a treat-all hepatitis C treatment strategy at global, regional and country levels: A modelling study. J Viral Hepat. 2019 12; 26(12):1388-1403. Trickey A, Fraser H, Lim AG, Walker JG, Peacock A, Colledge S, Leung J, Grebely J, Larney S, Martin NK, Degenhardt L, Hickman M, May MT, Vickerman P. PMID: 31392812; PMCID: PMC10401696.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    70. Scaling Up Hepatitis C Prevention and Treatment Interventions for Achieving Elimination in the United States: A Rural and Urban Comparison. Am J Epidemiol. 2019 08 01; 188(8):1539-1551. Fraser H, Vellozzi C, Hoerger TJ, Evans JL, Kral AH, Havens J, Young AM, Stone J, Handanagic S, Hariri S, Barbosa C, Hickman M, Leib A, Martin NK, Nerlander L, Raymond HF, Page K, Zibbell J, Ward JW, Vickerman P. PMID: 31150044; PMCID: PMC7415256.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    71. Chronic hepatitis B virus case-finding in UK populations born abroad in intermediate or high endemicity countries: an economic evaluation. BMJ Open. 2019 06 28; 9(6):e030183. Martin NK, Vickerman P, Khakoo S, Ghosh A, Ramsay M, Hickman M, Williams J, Miners A. PMID: 31256040; PMCID: PMC6609059.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansPHPublic Health
    72. Cost-effectiveness and budgetary impact of HCV treatment with direct-acting antivirals in India including the risk of reinfection. PLoS One. 2019; 14(6):e0217964. Chaillon A, Mehta SR, Hoenigl M, Solomon SS, Vickerman P, Hickman M, Skaathun B, Martin NK. PMID: 31170246; PMCID: PMC6553784.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    73. The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study. Lancet Gastroenterol Hepatol. 2019 06; 4(6):435-444. Trickey A, Fraser H, Lim AG, Peacock A, Colledge S, Walker JG, Leung J, Grebely J, Larney S, Martin NK, Hickman M, Degenhardt L, May MT, Vickerman P. PMID: 30981685; PMCID: PMC6698583.
      View in: PubMed   Mentions: 75     Fields:    Translation:HumansPHPublic Health
    74. Primary Incidence of Hepatitis C Virus Infection Among HIV-Infected Men Who Have Sex With Men in San Diego, 2000-2015. Open Forum Infect Dis. 2019 Apr; 6(4):ofz160. Chaillon A, Sun X, Cachay ER, Looney D, Wyles D, Garfein RS, Martin TCS, Jain S, Mehta SR, Smith DM, Little SJ, Martin NK, Martin NK. PMID: 31041355; PMCID: PMC6483132.
      View in: PubMed   Mentions: 16  
    75. Evaluating the impact of global fund withdrawal on needle and syringe provision, cost and use among people who inject drugs in Tijuana, Mexico: a costing analysis. BMJ Open. 2019 01 29; 9(1):e026298. Cepeda JA, Burgos JL, Kahn JG, Padilla R, Meza Martinez PE, Segovia LA, Gaines T, Abramovitz D, Rangel G, Magis-Rodriguez C, Vickerman P, Strathdee SA, Martin NK. PMID: 30700490; PMCID: PMC6352756.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    76. Hepatitis case finding among migrants in primary care. Lancet Gastroenterol Hepatol. 2019 01; 4(1):3-4. Hickman M, Mandel S, Vickerman P, Miners A, Martin N. PMID: 30477809.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    77. Mathematical modeling of hepatitis c virus (HCV) prevention among people who inject drugs: A review of the literature and insights for elimination strategies. J Theor Biol. 2019 11 21; 481:194-201. Pitcher AB, Borquez A, Skaathun B, Martin NK. PMID: 30452959; PMCID: PMC6522340.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    78. Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis. Lancet Infect Dis. 2018 12; 18(12):1397-1409. Stone J, Fraser H, Lim AG, Walker JG, Ward Z, MacGregor L, Trickey A, Abbott S, Strathdee SA, Abramovitz D, Maher L, Iversen J, Bruneau J, Zang G, Garfein RS, Yen YF, Azim T, Mehta SH, Milloy MJ, Hellard ME, Sacks-Davis R, Dietze PM, Aitken C, Aladashvili M, Tsertsvadze T, Mravcík V, Alary M, Roy E, Smyrnov P, Sazonova Y, Young AM, Havens JR, Hope VD, Desai M, Heinsbroek E, Hutchinson SJ, Palmateer NE, McAuley A, Platt L, Martin NK, Altice FL, Hickman M, Vickerman P. PMID: 30385157; PMCID: PMC6280039.
      View in: PubMed   Mentions: 87     Fields:    Translation:HumansPHPublic Health
    79. Tuberculosis Treatment Monitoring by Video Directly Observed Therapy in 5 Health Districts, California, USA. Emerg Infect Dis. 2018 10; 24(10):1806-1815. Garfein RS, Liu L, Cuevas-Mota J, Collins K, Muñoz F, Catanzaro DG, Moser K, Higashi J, Al-Samarrai T, Kriner P, Vaishampayan J, Cepeda J, Bulterys MA, Martin NK, Rios P, Raab F. PMID: 30226154; PMCID: PMC6154139.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansCTClinical Trials
    80. Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework. Liver Int. 2019 01; 39(1):20-30. Day E, Hellard M, Treloar C, Bruneau J, Martin NK, Øvrehus A, Dalgard O, Lloyd A, Dillon J, Hickman M, Byrne J, Litwin A, Maticic M, Bruggmann P, Midgard H, Norton B, Trooskin S, Lazarus JV, Grebely J, International Network on Hepatitis in Substance Users (INHSU). PMID: 30157316; PMCID: PMC6868526.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansPHPublic Health
    81. The effect of public health-oriented drug law reform on HIV incidence in people who inject drugs in Tijuana, Mexico: an epidemic modelling study. Lancet Public Health. 2018 09; 3(9):e429-e437. Borquez A, Beletsky L, Nosyk B, Strathdee SA, Madrazo A, Abramovitz D, Rafful C, Morales M, Cepeda J, Panagiotoglou D, Krebs E, Vickerman P, Claude Boily M, Thomson N, Martin NK. PMID: 30122559; PMCID: PMC6211569.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansPHPublic Health
    82. Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Society-Lancet Commission. Lancet. 2018 07 28; 392(10144):312-358. Bekker LG, Alleyne G, Baral S, Cepeda J, Daskalakis D, Dowdy D, Dybul M, Eholie S, Esom K, Garnett G, Grimsrud A, Hakim J, Havlir D, Isbell MT, Johnson L, Kamarulzaman A, Kasaie P, Kazatchkine M, Kilonzo N, Klag M, Klein M, Lewin SR, Luo C, Makofane K, Martin NK, Mayer K, Millett G, Ntusi N, Pace L, Pike C, Piot P, Pozniak A, Quinn TC, Rockstroh J, Ratevosian J, Ryan O, Sippel S, Spire B, Soucat A, Starrs A, Strathdee SA, Thomson N, Vella S, Schechter M, Vickerman P, Weir B, Beyrer C. PMID: 30032975; PMCID: PMC6323648.
      View in: PubMed   Mentions: 132     Fields:    Translation:Humans
    83. Potential impact of implementing and scaling up harm reduction and antiretroviral therapy on HIV prevalence and mortality and overdose deaths among people who inject drugs in two Russian cities: a modelling study. Lancet HIV. 2018 10; 5(10):e578-e587. Cepeda JA, Eritsyan K, Vickerman P, Lyubimova A, Shegay M, Odinokova V, Beletsky L, Borquez A, Hickman M, Beyrer C, Martin NK. PMID: 30033374; PMCID: PMC6188805.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    84. Modelling the impact of a national scale-up of interventions on hepatitis C virus transmission among people who inject drugs in Scotland. Addiction. 2018 11; 113(11):2118-2131. Fraser H, Mukandavire C, Martin NK, Goldberg D, Palmateer N, Munro A, Taylor A, Hickman M, Hutchinson S, Vickerman P. PMID: 29781207; PMCID: PMC6250951.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    85. Understanding and Addressing Hepatitis C Virus Reinfection Among Men Who Have Sex with Men. Infect Dis Clin North Am. 2018 06; 32(2):395-405. Martin TCS, Rauch A, Salazar-Vizcaya L, Martin NK, Martin NK. PMID: 29778262; PMCID: PMC5973544.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCellsPHPublic Health
    86. Cost of provision of opioid substitution therapy provision in Tijuana, Mexico. Harm Reduct J. 2018 05 23; 15(1):28. Burgos JL, Cepeda JA, Kahn JG, Mittal ML, Meza E, Lazos RRP, Vargas PC, Vickerman P, Strathdee SA, Martin NK. PMID: 29792191; PMCID: PMC5967039.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    87. Impact of current and scaled-up levels of hepatitis C prevention and treatment interventions for people who inject drugs in three UK settings-what is required to achieve the WHO's HCV elimination targets? Addiction. 2018 May 17. Ward Z, Platt L, Sweeney S, Hope VD, Maher L, Hutchinson S, Palmateer N, Smith J, Craine N, Taylor A, Martin N, Ayres R, Dillon J, Hickman M, Vickerman P. PMID: 29774607; PMCID: PMC6175066.
      View in: PubMed   Mentions: 15     Fields:    
    88. Curbing the hepatitis C virus epidemic in Pakistan: the impact of scaling up treatment and prevention for achieving elimination. Int J Epidemiol. 2018 04 01; 47(2):550-560. Lim AG, Qureshi H, Mahmood H, Hamid S, Davies CF, Trickey A, Glass N, Saeed Q, Fraser H, Walker JG, Mukandavire C, Hickman M, Martin NK, May MT, Averhoff F, Vickerman P. PMID: 29309592; PMCID: PMC5913612.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansPHPublic Health
    89. Is hepatitis C virus elimination possible among people living with HIV and what will it take to achieve it? J Int AIDS Soc. 2018 04; 21 Suppl 2:e25062. Martin NK, Boerekamps A, Hill AM, Rijnders BJA. PMID: 29633560; PMCID: PMC5978712.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansPHPublic Health
    90. Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe. J Hepatol. 2018 03; 68(3):402-411. Fraser H, Martin NK, Brummer-Korvenkontio H, Carrieri P, Dalgard O, Dillon J, Goldberg D, Hutchinson S, Jauffret-Roustide M, Kåberg M, Matser AA, Maticic M, Midgard H, Mravcik V, Øvrehus A, Prins M, Reimer J, Robaeys G, Schulte B, van Santen DK, Zimmermann R, Vickerman P, Hickman M. PMID: 29080808; PMCID: PMC5841161.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansPHPublic Health
    91. Behavioural, not biological, factors drive the HCV epidemic among HIV-positive MSM: HCV and HIV modelling analysis including HCV treatment-as-prevention impact. Int J Epidemiol. 2017 10 01; 46(5):1582-1592. MacGregor L, Martin NK, Mukandavire C, Hickson F, Weatherburn P, Hickman M, Vickerman P. PMID: 28605503; PMCID: PMC5837478.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCellsPHPublic Health
    92. Scaling-up HCV prevention and treatment interventions in rural United States-model projections for tackling an increasing epidemic. Addiction. 2018 Jan; 113(1):173-182. Fraser H, Zibbell J, Hoerger T, Hariri S, Vellozzi C, Martin NK, Kral AH, Hickman M, Ward JW, Vickerman P. PMID: 28734093; PMCID: PMC6211174.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansPHPublic Health
    93. New developments and opportunities for preventing hepatitis C virus (HCV) among people who use and inject drugs-announcing an Addiction series. Addiction. 2017 07; 112(7):1126-1127. Hickman M, Grebely J, Bruneau J, Coffin P, Degenhardt L, Hutchinson S, Larney S, Martin N, Treloar C, Vickerman P. PMID: 28586551.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    94. HIV treatment as prevention among people who inject drugs - a re-evaluation of the evidence. Int J Epidemiol. 2017 04 01; 46(2):466-478. Fraser H, Mukandavire C, Martin NK, Hickman M, Cohen MS, Miller WC, Vickerman P. PMID: 27524816; PMCID: PMC5837590.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    95. Modeling Combination HCV Prevention among HIV-infected Men Who Have Sex With Men and People Who Inject Drugs. AIDS Rev. 2017 Apr - Jun; 19(2):97-104. Martin NK, Skaathun B, Vickerman P, Stuart D. PMID: 28534885; PMCID: PMC5560483.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    96. How to eliminate HCV infection by antiviral treatment. J Hepatol. 2017 07; 67(1):5-6. Martin NK, Vickerman P, Hickman M. PMID: 28323120.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    97. Modelling the impact of incarceration and prison-based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland. Addiction. 2017 Jul; 112(7):1302-1314. Stone J, Martin NK, Hickman M, Hutchinson SJ, Aspinall E, Taylor A, Munro A, Dunleavy K, Peters E, Bramley P, Hayes PC, Goldberg DJ, Vickerman P. PMID: 28257600; PMCID: PMC5461206.
      View in: PubMed   Mentions: 43     Fields:    Translation:Humans
    98. Treatment and primary prevention in people who inject drugs for chronic hepatitis C infection: is elimination possible in a high-prevalence setting? Addiction. 2017 Jul; 112(7):1290-1299. Gountas I, Sypsa V, Anagnostou O, Martin N, Vickerman P, Kafetzopoulos E, Hatzakis A. PMID: 28107585; PMCID: PMC5553636.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansPHPublic Health
    99. Association of BCG, DTP, and measles containing vaccines with childhood mortality: systematic review. BMJ. 2016 Oct 13; 355:i5170. Higgins JP, Soares-Weiser K, López-López JA, Kakourou A, Chaplin K, Christensen H, Martin NK, Sterne JA, Reingold AL. PMID: 27737834; PMCID: PMC5063034.
      View in: PubMed   Mentions: 225     Fields:    Translation:HumansPHPublic Health
    100. Hepatitis C virus prevention and treatment prioritization-ethical, economic and evidential dimensions of early rather than delayed treatment for people who inject drugs. Addiction. 2017 02; 112(2):201-203. Hickman M, Martin NK, Huxtable R. PMID: 27514647; PMCID: PMC5233591.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    101. A matched comparison study of hepatitis C treatment outcomes in the prison and community setting, and an analysis of the impact of prison release or transfer during therapy. J Viral Hepat. 2016 12; 23(12):1009-1016. Aspinall EJ, Mitchell W, Schofield J, Cairns A, Lamond S, Bramley P, Peters SE, Valerio H, Tomnay J, Goldberg DJ, Mills PR, Barclay ST, Fraser A, Dillon JF, Martin NK, Hickman M, Hutchinson SJ. PMID: 27509844; PMCID: PMC5558600.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    102. The perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia. Lancet. 2016 Sep 17; 388(10050):1228-48. Altice FL, Azbel L, Stone J, Brooks-Pollock E, Smyrnov P, Dvoriak S, Taxman FS, El-Bassel N, Martin NK, Booth R, Stöver H, Dolan K, Vickerman P. PMID: 27427455; PMCID: PMC5087988.
      View in: PubMed   Mentions: 120     Fields:    Translation:Humans
    103. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet. 2016 Sep 10; 388(10049):1081-1088. Stanaway JD, Flaxman AD, Naghavi M, Fitzmaurice C, Vos T, Abubakar I, Abu-Raddad LJ, Assadi R, Bhala N, Cowie B, Forouzanfour MH, Groeger J, Hanafiah KM, Jacobsen KH, James SL, MacLachlan J, Malekzadeh R, Martin NK, Mokdad AA, Mokdad AH, Murray CJL, Plass D, Rana S, Rein DB, Richardus JH, Sanabria J, Saylan M, Shahraz S, So S, Vlassov VV, Weiderpass E, Wiersma ST, Younis M, Yu C, El Sayed Zaki M, Cooke GS. PMID: 27394647; PMCID: PMC5100695.
      View in: PubMed   Mentions: 527     Fields:    Translation:Humans
    104. Reply. Hepatology. 2016 11; 64(5):1822-1823. Martin NK, Vickerman P, Hickman M. PMID: 27112633.
      View in: PubMed   Mentions:    Fields:    
    105. The Potential Impact of a Hepatitis C Vaccine for People Who Inject Drugs: Is a Vaccine Needed in the Age of Direct-Acting Antivirals? PLoS One. 2016; 11(5):e0156213. Stone J, Martin NK, Hickman M, Hellard M, Scott N, McBryde E, Drummer H, Vickerman P. PMID: 27224423; PMCID: PMC4880220.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCellsPHPublic Health
    106. Overlapping substance using high-risk groups and infectious diseases: how dynamic modelling can evaluate risk and target HIV prevention. Addiction. 2016 09; 111(9):1512-5. Martin NK, Vickerman P, Hickman M, Patterson TL, Rand E, Abramovitz D, Strathdee SA. PMID: 27075692; PMCID: PMC4983200.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    107. New treatments for hepatitis C virus (HCV): scope for preventing liver disease and HCV transmission in England. J Viral Hepat. 2016 08; 23(8):631-43. Harris RJ, Martin NK, Rand E, Mandal S, Mutimer D, Vickerman P, Ramsay ME, De Angelis D, Hickman M, Harris HE. PMID: 27025238; PMCID: PMC4982023.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansPHPublic Health
    108. HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact. J Viral Hepat. 2015 Apr; 22(4):399-408. Martin NK, Foster GR, Vilar J, Ryder S, Cramp ME, Gordon F, Dillon JF, Craine N, Busse H, Clements A, Hutchinson SJ, Ustianowski A, Ramsay M, Goldberg DJ, Irving W, Hope V, De Angelis D, Lyons M, Vickerman P, Hickman M. PMID: 25288193; PMCID: PMC4409099.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansCells
    109. Assessing the cost-effectiveness of finding cases of hepatitis C infection in UK migrant populations and the value of further research. J Viral Hepat. 2014; 21(9):616-23. Miners AH, Martin NK, Ghosh A, Hickman M, Vickerman P. PMID: 24215210.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    110. A general reaction-diffusion model of acidity in cancer invasion. J Math Biol. 2014 Apr; 68(5):1199-224. McGillen JB, Gaffney EA, Martin NK, Maini PK. PMID: 23536240.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    111. C-reactive protein is a useful predictor of metronidazole treatment failure in mild-to-moderate Clostridium difficile infection. Eur J Gastroenterol Hepatol. 2013 Jan; 25(1):33-6. Farne HA, Martin NK, Main J, Orchard T, Tyrrell-Price J. PMID: 23026925.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    112. Could low dead-space syringes really reduce HIV transmission to low levels? Int J Drug Policy. 2013 Jan; 24(1):8-14. Vickerman P, Martin NK, Hickman M. PMID: 23206493.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsPHPublic Health
    113. Pancreatic insufficiency in patients with HIV infection: role of didanosine questioned. HIV Med. 2013 Mar; 14(3):161-6. Martin TC, Martin TC, Scourfield A, Rockwood N, Martin NK, Patel N, Nelson M, Gazzard BG. PMID: 22994793.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    114. Predicting the safety and efficacy of buffer therapy to raise tumour pHe: an integrative modelling study. Br J Cancer. 2012 Mar 27; 106(7):1280-7. Martin NK, Robey IF, Gaffney EA, Gillies RJ, Gatenby RA, Maini PK. PMID: 22382688; PMCID: PMC3314784.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansAnimals
    115. Bicarbonate and dichloroacetate: evaluating pH altering therapies in a mouse model for metastatic breast cancer. BMC Cancer. 2011 Jun 10; 11:235. Robey IF, Martin NK. PMID: 21663677; PMCID: PMC3125283.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansAnimalsCells
    116. A mathematical model of tumour and blood pHe regulation: The HCO3-/CO2 buffering system. Math Biosci. 2011 Mar; 230(1):1-11. Martin NK, Gaffney EA, Gatenby RA, Gillies RJ, Robey IF, Maini PK. PMID: 21167185; PMCID: PMC3045481.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimalsCells
    117. Tumour-stromal interactions in acid-mediated invasion: a mathematical model. J Theor Biol. 2010 Dec 07; 267(3):461-70. Martin NK, Gaffney EA, Gatenby RA, Maini PK. PMID: 20816684; PMCID: PMC3005191.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansAnimalsCells
    118. Leaky vessels as a potential source of stromal acidification in tumours. J Theor Biol. 2010 Dec 07; 267(3):454-60. Martin NK, Gaffney EA, Gatenby RA, Maini PK. PMID: 20699102; PMCID: PMC2963718.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimals
    Natasha's Networks
    Concepts (299)
    Derived automatically from this person's publications.
    _
    Co-Authors (80)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _